Printer Friendly

COURT RULES THAT SIEMENS-PACESETTER DEVICE INFRINGES MEDTRONIC PATENT

 COURT RULES THAT SIEMENS-PACESETTER DEVICE
 INFRINGES MEDTRONIC PATENT
 MINNEAPOLIS, Feb. 14 /PRNewswire/ -- The United States District Court for the Northern District of Illinois ruled today that the Sensolog III cardiac pacemaker manufactured by Siemens-Pacesetter, Inc., Sylmar, Calif., infringes the activity rate responsive patent held by Medtronic, Inc. (NYSE: MDT).
 The court granted Medtronic's motion to enjoin Siemens-Pacesetter from further manufacturing, using or selling the Sensolog III device. In September 1991, the court ruled that Siemens's Sensolog pacemaker, predecessor to the Sensolog III, and its Synchrony pacemaker also infringed and the court also enjoined them from future sale. However, the court ruled today that a full trial would be required to determine whether the Siemens Synchrony II and Solus pacemakers also infringe the Medtronic patent.
 William W. George, president and chief executive officer, said, "Medtronic is committed to the protection of its intellectual property and we are pleased that the court supported our position on the Sensolog III. However, in view of the earlier ruling that Synchrony infringed Medtronic's rate responsive patent, we are deeply disappointed that the court would not enjoin the Siemens Synchrony II and Solus devices without a full trial. We will, of course, request a full trial in order to prove that these devices infringe our patent and should be removed from the market."
 Medtronic counsel said they also would immediately seek a substantial damage award related to the Sensolog, Sensolog III and Synchrony pacemakers.
 The pioneering Medtronic activity rate responsive patent revolutionized the pacing industry when introduced in the Medtronic Activitrax(R) pacemaker in 1984. It relates to technology that gives pacemakers the capability of automatically adjusting their rate of impulses to the requirements of the patient's circulatory system. Medtronic refined the technology in the Activitrax II, Synergyst(TM), Synergyst II, Legend(TM), Legend II, and Elite(TM) pacemakers.
 Medtronic, Inc., headquartered in Minneapolis, is a leading developer and manufacturer of biomedical devices for improving cardiovascular and neurological health.
 -0- 2/14/92
 /CONTACT: Dale Beumer, investor relations, 612-574-3038, or Dick Reid, 612-574-3052, both of Medtronic/
 (MDT) CO: Medtronic, Inc.; Siemens-Pacesetter, Inc. ST: Minnesota, California IN: MTC SU:


JT -- NY083 -- 0443 02/14/92 18:54 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 14, 1992
Words:361
Previous Article:AMERIWOOD ACQUIRES ITS STOCK HELD BY ATLANTIS; SETTLES ALL PENDING LAWSUITS
Next Article:BOW VALLEY ANNOUNCES 1991 NET INCOME OF $10.1 MILLION BEFORE CEILING TEST WRITE DOWN
Topics:


Related Articles
SIEMENS, MEDTRONIC ANNOUNCE SETTLEMENT OF PATENT LITIGATION
GERMAN COURT RULES THAT THREE BIOTRONIK DEVICES INFRINGE MEDTRONIC PATENTS
Damages announced in Johnson & Johnson/Cordis patent infringement suit against Medtronic.
Johnson & Johnson awarded $425 million in patent infringement.
Medtronic loses patent suit to J&J.
Cordis wins recent round against Medtronic and Boston Scientific in Stent lawsuit.
Court of Appeals Upholds Verdicts in Favor of Cordis on Patents Infringed by Medtronic and Boston Scientific.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters